GlassScriptPhysician profile
Tulio R Ortega
NPI 1114013364
$319,134.98
in general payments reported to CMS, 2019-2025
23 companies · $80K in 2025
The $80K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $9,204 · 2021: $16K · 2022: $86K · 2023: $68K · 2024: $59K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $172K · Consulting Fee: $16K · Food and Beverage: $9,930 · Travel and Lodging: $8,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $172,325.00 |
| Consulting Fee | $15,855.00 |
| Food and Beverage | $9,929.86 |
| Travel and Lodging | $8,776.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $190,193.51 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $67,857.13 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $26,546.10 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $21,272.66 | 2020-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $8,653.94 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $865.31 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $707.51 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $693.84 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Avanir Pharmaceuticals, INC. | $413.31 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $318.89 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $309.36 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $253.72 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $235.78 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.48 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $186.04 | 2023-2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $155.22 | 2021-2023 | Qelbree |
| Corium, LLC | $60.06 | 2022-2025 | Azstarys |
| Janssen Scientific Affairs, LLC | $49.67 | 2023 | |
| Bausch Health US, LLC | $41.55 | 2020 | |
| Merck Sharp & Dohme LLC | $40.04 | 2023 | Belsomra |
| Neos Therapeutics, LP | $33.86 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $24.56 | 2022 | |
| Indivior INC. | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tulio Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.